GPR15 Antibody

What experimental applications have GPR15 antibodies been validated for?

GPR15 antibodies have been successfully validated for multiple applications including:

• Western Blot (WB): Most commercial antibodies work at concentrations of 0.5-1 μg/mL

• Immunohistochemistry (IHC-P): Typically used at concentrations of 5-10 μg/mL for formalin-fixed, paraffin-embedded tissues

• Flow Cytometry: Recommended usage is 5 μL per million cells or 5 μL per 100 μL of whole blood

• Immunocytochemistry (ICC): Starting concentration of 5 μg/mL is recommended

• ELISA: Validated by some manufacturers though optimal dilutions vary by assay format

Different antibody clones may perform better in specific applications, so validation for your particular experimental system is essential.

What is the significance of specific GPR15 domains when selecting an antibody?

When selecting a GPR15 antibody, the target domain significantly impacts experimental outcomes:

• N-terminal antibodies (targeting amino acids 1-50) are effective for Western blot and can detect total receptor levels regardless of phosphorylation state

• Extracellular domain antibodies are particularly valuable for flow cytometry of live cells and for detecting surface expression

• C-terminal antibodies can detect the receptor in various conformational states but may be affected by protein interactions or post-translational modifications

Domain-specific antibodies enable distinct aspects of receptor biology to be studied, from trafficking to signaling activation.

How does GPR15 antibody performance vary across species?

Species cross-reactivity is an important consideration:

Some antibodies claim cross-reactivity with human, mouse, and rat GPR15, but experimental validation is recommended as sequence variations exist between species, particularly in the terminal regions .

What are the optimal conditions for detecting GPR15 by Western blot?

Western blot optimization for GPR15 requires attention to several factors:

• Expected molecular weight varies from predicted 41 kDa to observed bands at 50-68 kDa due to post-translational modifications

• Recommended antibody concentrations range from 0.5-1 μg/mL

• Peptide blocking controls are essential to confirm specificity, as demonstrated in Abcam's validation where specific peptide abolished the signal while unrelated peptide did not

• Human spleen and heart lysates have been successfully used as positive controls

GPR15 may appear as multiple bands due to glycosylation, oligomerization (reportedly forms homotrimers), or proteolytic processing.

How should flow cytometry protocols be optimized for GPR15 detection?

For optimal flow cytometry results with GPR15 antibodies:

• Start with 5 μL antibody per million cells in 100 μL staining volume

• Include appropriate isotype controls (e.g., Mouse IgG2a, κ for human GPR15 detection)

• GPR15-transfected cell lines serve as excellent positive controls

• Co-staining with lineage markers (CD3, CD4, CD8, CD19) helps identify specific GPR15-expressing populations

• Under naive conditions, expect approximately 2-3% of living cells in lymphoid tissues to express GPR15

• Store conjugated antibodies between 2-8°C and protect from light; do not freeze

Optimization through titration is recommended for each specific experimental setup.

What controls are essential when working with GPR15 antibodies?

Rigorous controls are critical for GPR15 antibody experiments:

• Positive controls: GPR15-transfected HEK293 cells (human embryonic kidney cell line)

• Negative controls: Untransfected cells or GPR15-negative cell lines

• Isotype controls: Mouse IgG2a for human GPR15 monoclonal antibodies

• Peptide blocking: Pre-incubation with immunizing peptide should abolish specific signal

• Genetic controls: Tissues from Gpr15^-/-^ (knockout) mice, where available

These controls help distinguish specific from non-specific signals and validate antibody performance across applications.

How can GPR15 antibodies be used to investigate receptor regulation during inflammation?

GPR15 and its ligand show complex regulation during inflammatory processes:

• In autoimmune skin inflammation models, GPR15 mRNA is significantly downregulated in inflamed skin while its ligand GPR15L is markedly upregulated

• Flow cytometric analysis reveals changes in GPR15-expressing cell populations during inflammation, with increased proportions of GPR15+CD3+ cells in draining lymph nodes

• Immunohistochemical staining of sequential tissue sections taken during disease progression can reveal spatial and temporal changes in receptor expression

• Comparison between wild-type and Gpr15^-/-^ mice shows increased γδ T cell infiltration in dermal tissues in absence of GPR15, suggesting its role in regulating inflammatory cell recruitment

This reciprocal regulation pattern suggests a feedback mechanism that may be important for resolving inflammation.

What methodological approaches reveal GPR15's role in cancer immunology?

For studying GPR15 in cancer immunology, consider these approaches:

• Flow cytometry with GPR15 antibodies combined with tumor-infiltrating lymphocyte markers can assess immune cell infiltration patterns

• Analysis of human cancer datasets (TCGA) has shown that lower GPR15 expression correlates with poor survival in colon cancer

• In AOM/DSS colitis-associated colon cancer models, Gpr15-knockout mice show increased colonic polyps and reduced survival compared to heterozygous controls

• GPR15 ligand (GPR15L) administration increased CD45+ cell infiltration and enhanced TNFα expression on CD4+ and CD8+ T cells at tumor sites

These findings suggest GPR15 plays a protective role in anti-tumor immunity by regulating T cell function and infiltration.

How can researchers study the interaction between GPR15 and its ligand GPR15L?

To investigate GPR15-GPR15L interactions:

• qPCR analysis has shown that GPR15 and GPR15L are reciprocally regulated during inflammation

• GPR15L treatment studies can assess downstream effects on immune cell recruitment and activation

• Co-immunoprecipitation experiments using GPR15 antibodies can identify protein complexes formed upon ligand binding

• Proximity ligation assays can visualize GPR15-GPR15L interactions in situ

• In vivo application of GPR15L in AP-57-NPs-H hydrogel formulations has been reported and could be used to study therapeutic effects in skin inflammation models

These approaches help elucidate the signaling mechanisms and functional outcomes of GPR15 activation.

How should researchers address discrepancies in GPR15 detection across different experiments?

When encountering inconsistent GPR15 detection:

• Consider tissue-specific expression patterns: GPR15 is expressed at varying levels in different tissues and under different conditions

• Verify mRNA expression: Sometimes GPR15 mRNA is detectable while protein levels remain below detection limits

• Check for receptor internalization: GPCRs like GPR15 may be internalized after ligand binding, affecting surface detection

• Molecular weight variations: Expected band sizes range from predicted 41 kDa to observed 50-68 kDa due to post-translational modifications

• Cell-specific expression: In lymphoid tissues, only 2-3% of cells express GPR15, predominantly on CD8+ T cells during inflammation

Complementary approaches like qPCR alongside protein detection can help resolve discrepancies.

What factors influence the quantitative interpretation of GPR15 expression data?

For accurate quantitative analysis of GPR15 expression:

• Consider baseline expression levels: Under naive conditions, approximately 2-3% of lymphoid cells express GPR15

• Account for disease state: Expression patterns change during inflammation, with increased proportions of GPR15+CD3+ cells

• Cell type specificity: GPR15 is predominantly expressed on CD8+ T cells during inflammation, with minimal expression on B cells (CD19+)

• Receptor regulation dynamics: GPR15 mRNA is downregulated in inflamed tissues while GPR15L is upregulated, suggesting complex feedback regulation

• Technical variation: Different antibody clones, detection methods, and experimental conditions can affect quantitative measurements

Standardization across experiments using consistent controls helps ensure reliable quantitative comparisons.

How can researchers distinguish between specific and non-specific binding in complex tissues?

To differentiate specific from non-specific GPR15 antibody binding:

• Use multiple antibody clones targeting different epitopes to confirm staining patterns

• Include peptide competition controls, where pre-incubation with the immunizing peptide should eliminate specific staining

• Compare with isotype control antibodies of the same concentration

• Include Gpr15^-/-^ tissues as negative controls where available

• Use sequential sections for complementary detection methods (IHC, in situ hybridization)

• In flow cytometry, careful gating strategies based on isotype controls and known expression patterns are essential

Complex tissues like skin or intestine may require additional optimization of antigen retrieval and blocking steps.

How might GPR15 antibodies contribute to therapeutic development for inflammatory diseases?

GPR15 antibodies can facilitate therapeutic research through:

• Target validation: Studies in Gpr15^-/-^ mice demonstrated aggravated disease in antibody-mediated skin inflammation models, suggesting GPR15 activation could be therapeutically beneficial

• Biomarker development: Flow cytometric analysis of GPR15+ immune cells could serve as a disease activity marker

• Mechanism elucidation: GPR15 appears to limit γδ T cell recruitment to inflamed tissues, providing a potential mechanism for intervention

• Therapeutic screening: GPR15 antibodies can help screen compounds that modulate receptor activity

• Preclinical models: GPR15L (also known as AP-57 or C10orf99) can be applied in hydrogel formulations to the skin, enabling potential therapeutic studies

These approaches could lead to novel treatments for pemphigoid diseases and other inflammatory conditions.

What methodological advances would improve GPR15 detection in clinical samples?

Future methodological improvements for clinical GPR15 analysis:

• Multiplexed imaging approaches combining GPR15 detection with other immune markers

• Single-cell analysis techniques to better characterize GPR15+ cells in heterogeneous populations

• More sensitive detection methods for tissues with low GPR15 expression

• Standardized protocols for flow cytometry with clinical samples

• Development of humanized GPR15 antibodies for potential therapeutic applications

• Mass cytometry (CyTOF) panels including GPR15 for comprehensive immune profiling

These advances would enhance our understanding of GPR15 biology in human disease and facilitate translation to clinical applications.